Literature DB >> 27757314

Human cytomegalovirus-based immunotherapy to treat glioblastoma: Into the future.

Sanne Duinkerken1, Yvette van Kooyk1, Juan J Garcia-Vallejo1.   

Abstract

Glioblastoma multiforme (GBM) is the most aggressive brain tumor and median survival time with current therapies is only 14.6 mo. Although multiple immunotherapeutic strategies are being explored, efficacy remains poor. In order to improve immunotherapy for GBM, we propose to combine currently used endogenous with human cytomegalovirus (HCMV) specific antigens expressed on cancer cells.

Entities:  

Keywords:  C-type lectin receptor; HCMV; dendritic cell; glioblastoma; immunotherapy; vaccination

Year:  2016        PMID： 27757314      PMCID： PMC5048761          DOI： 10.1080/2162402X.2016.1214791

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Consensus on the role of human cytomegalovirus in glioblastoma.

Authors:  Kristine Dziurzynski; Susan M Chang; Amy B Heimberger; Robert F Kalejta; Stuart R McGregor Dallas; Martine Smit; Liliana Soroceanu; Charles S Cobbs
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

2.  A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Authors:  James Schuster; Rose K Lai; Lawrence D Recht; David A Reardon; Nina A Paleologos; Morris D Groves; Maciej M Mrugala; Randy Jensen; Joachim M Baehring; Andrew Sloan; Gary E Archer; Darell D Bigner; Scott Cruickshank; Jennifer A Green; Tibor Keler; Thomas A Davis; Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2015-01-13       Impact factor: 12.300

3.  Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma.

Authors:  Liliana Soroceanu; Lisa Matlaf; Sabeena Khan; Armin Akhavan; Eric Singer; Vladimir Bezrookove; Stacy Decker; Saleena Ghanny; Piotr Hadaczek; Henrik Bengtsson; John Ohlfest; Maria-Gloria Luciani-Torres; Lualhati Harkins; Arie Perry; Hong Guo; Patricia Soteropoulos; Charles S Cobbs
Journal:  Cancer Res       Date:  2015-08-01       Impact factor: 12.701

4.  DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

Authors:  Wim Maes; Georgina Galicia Rosas; Bert Verbinnen; Louis Boon; Steven De Vleeschouwer; Jan L Ceuppens; Stefaan W Van Gool
Journal:  Neuro Oncol       Date:  2009-03-31       Impact factor: 12.300

5.  Skin-resident antigen-presenting cells: instruction manual for vaccine development.

Authors:  Cynthia M Fehres; Juan J Garcia-Vallejo; Wendy W J Unger; Yvette van Kooyk
Journal:  Front Immunol       Date:  2013-06-20       Impact factor: 7.561

6.  Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression.

Authors:  Wendy Wj Unger; Christian T Mayer; Steef Engels; Christina Hesse; Maurizio Perdicchio; Franz Puttur; Ingeborg Streng-Ouwehand; Manja Litjens; Hakan Kalay; Luciana Berod; Tim Sparwasser; Yvette van Kooyk
Journal:  Oncoimmunology       Date:  2014-10-31       Impact factor: 8.110

7.  B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients.

Authors:  Aparajita Baral; Hong Xing Ye; Pu Cha Jiang; Yu Yao; Ying Mao
Journal:  Oncol Lett       Date:  2014-06-19       Impact factor: 2.967

8.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962

9.  Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.

Authors:  Duane A Mitchell; Kristen A Batich; Michael D Gunn; Min-Nung Huang; Luis Sanchez-Perez; Smita K Nair; Kendra L Congdon; Elizabeth A Reap; Gary E Archer; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; April Coan; Roger E McLendon; David A Reardon; James J Vredenburgh; Darell D Bigner; John H Sampson
Journal:  Nature       Date:  2015-03-11       Impact factor: 49.962

Review 10.  Targeting Aggressive Cancer Stem Cells in Glioblastoma.

Authors:  Tracy Seymour; Anna Nowak; Foteini Kakulas
Journal:  Front Oncol       Date:  2015-07-20       Impact factor: 6.244
  10 in total
  1 in total

1.  Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.

Authors:  Yung-Chiang Liu; I-Chi Lee; Pin-Yuan Chen
Journal:  J Neurooncol       Date:  2018-01-22       Impact factor: 4.130
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.